Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults

Joyce K. Keithley, Barbara Swanson, Susan L. Mikolaitis, Mark Demeo, Janice M. Zeller, Lou Fogg, Jehan Adamji

Research output: Contribution to journalArticle

Abstract

Background. Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets. Methods. Participants were randomly assigned to take 1.33 grams of glucomannan or identically looking placebo capsules with 236.6 mL (8 ounces) of water one hour before breakfast, lunch, and dinner for 8 weeks. The primary efficacy outcome was change in body weight after 8 weeks. Other efficacy outcomes were changes in body composition, hunger/fullness, and lipid and glucose concentrations. Safety outcomes included gastrointestinal symptoms/tolerance and serum liver enzymes and creatinine levels. Results. A total of 53 participants (18-65 years of age; BMI 25-35 kg/m2) were enrolled and randomized. The two groups did not differ with respect to baseline characteristics and compliance with the study supplement. At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (-. 40 ±. 06 and -. 43 ±. 07, resp.) or other efficacy outcomes or in any of the safety outcomes. Conclusions. Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters. This trial is registered with NCT00613600.

LanguageEnglish (US)
Article number610908
JournalJournal of Obesity
Volume2013
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Weight Loss
Safety
Hunger
Body Composition
Placebos
Lipids
Glucose
Lunch
Body Weight Changes
Breakfast
Water
Dietary Supplements
Capsules
Meals
Creatinine
Diet
(1-6)-alpha-glucomannan
Liver
Enzymes
Serum

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Keithley, J. K., Swanson, B., Mikolaitis, S. L., Demeo, M., Zeller, J. M., Fogg, L., & Adamji, J. (2013). Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. Journal of Obesity, 2013, [610908]. DOI: 10.1155/2013/610908

Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. / Keithley, Joyce K.; Swanson, Barbara; Mikolaitis, Susan L.; Demeo, Mark; Zeller, Janice M.; Fogg, Lou; Adamji, Jehan.

In: Journal of Obesity, Vol. 2013, 610908, 2013.

Research output: Contribution to journalArticle

Keithley, JK, Swanson, B, Mikolaitis, SL, Demeo, M, Zeller, JM, Fogg, L & Adamji, J 2013, 'Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults' Journal of Obesity, vol 2013, 610908. DOI: 10.1155/2013/610908
Keithley JK, Swanson B, Mikolaitis SL, Demeo M, Zeller JM, Fogg L et al. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. Journal of Obesity. 2013;2013. 610908. Available from, DOI: 10.1155/2013/610908
Keithley, Joyce K. ; Swanson, Barbara ; Mikolaitis, Susan L. ; Demeo, Mark ; Zeller, Janice M. ; Fogg, Lou ; Adamji, Jehan. / Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. In: Journal of Obesity. 2013 ; Vol. 2013.
@article{7fa735fefcfa4254acc5eb9f5624632b,
title = "Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults",
abstract = "Background. Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets. Methods. Participants were randomly assigned to take 1.33 grams of glucomannan or identically looking placebo capsules with 236.6 mL (8 ounces) of water one hour before breakfast, lunch, and dinner for 8 weeks. The primary efficacy outcome was change in body weight after 8 weeks. Other efficacy outcomes were changes in body composition, hunger/fullness, and lipid and glucose concentrations. Safety outcomes included gastrointestinal symptoms/tolerance and serum liver enzymes and creatinine levels. Results. A total of 53 participants (18-65 years of age; BMI 25-35 kg/m2) were enrolled and randomized. The two groups did not differ with respect to baseline characteristics and compliance with the study supplement. At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (-. 40 ±. 06 and -. 43 ±. 07, resp.) or other efficacy outcomes or in any of the safety outcomes. Conclusions. Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters. This trial is registered with NCT00613600.",
author = "Keithley, {Joyce K.} and Barbara Swanson and Mikolaitis, {Susan L.} and Mark Demeo and Zeller, {Janice M.} and Lou Fogg and Jehan Adamji",
year = "2013",
doi = "10.1155/2013/610908",
language = "English (US)",
volume = "2013",
journal = "Journal of Obesity",
issn = "2090-0708",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults

AU - Keithley,Joyce K.

AU - Swanson,Barbara

AU - Mikolaitis,Susan L.

AU - Demeo,Mark

AU - Zeller,Janice M.

AU - Fogg,Lou

AU - Adamji,Jehan

PY - 2013

Y1 - 2013

N2 - Background. Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets. Methods. Participants were randomly assigned to take 1.33 grams of glucomannan or identically looking placebo capsules with 236.6 mL (8 ounces) of water one hour before breakfast, lunch, and dinner for 8 weeks. The primary efficacy outcome was change in body weight after 8 weeks. Other efficacy outcomes were changes in body composition, hunger/fullness, and lipid and glucose concentrations. Safety outcomes included gastrointestinal symptoms/tolerance and serum liver enzymes and creatinine levels. Results. A total of 53 participants (18-65 years of age; BMI 25-35 kg/m2) were enrolled and randomized. The two groups did not differ with respect to baseline characteristics and compliance with the study supplement. At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (-. 40 ±. 06 and -. 43 ±. 07, resp.) or other efficacy outcomes or in any of the safety outcomes. Conclusions. Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters. This trial is registered with NCT00613600.

AB - Background. Few safe and effective dietary supplements are available to promote weight loss. We evaluated the safety and efficacy of glucomannan, a water-soluble fiber supplement, for achieving weight loss in overweight and moderately obese individuals consuming self-selected diets. Methods. Participants were randomly assigned to take 1.33 grams of glucomannan or identically looking placebo capsules with 236.6 mL (8 ounces) of water one hour before breakfast, lunch, and dinner for 8 weeks. The primary efficacy outcome was change in body weight after 8 weeks. Other efficacy outcomes were changes in body composition, hunger/fullness, and lipid and glucose concentrations. Safety outcomes included gastrointestinal symptoms/tolerance and serum liver enzymes and creatinine levels. Results. A total of 53 participants (18-65 years of age; BMI 25-35 kg/m2) were enrolled and randomized. The two groups did not differ with respect to baseline characteristics and compliance with the study supplement. At 8 weeks, there was no significant difference between the glucomannan and placebo groups in amount of weight loss (-. 40 ±. 06 and -. 43 ±. 07, resp.) or other efficacy outcomes or in any of the safety outcomes. Conclusions. Glucomannan supplements administered over 8 weeks were well tolerated but did not promote weight loss or significantly alter body composition, hunger/fullness, or lipid and glucose parameters. This trial is registered with NCT00613600.

UR - http://www.scopus.com/inward/record.url?scp=84896142216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896142216&partnerID=8YFLogxK

U2 - 10.1155/2013/610908

DO - 10.1155/2013/610908

M3 - Article

VL - 2013

JO - Journal of Obesity

T2 - Journal of Obesity

JF - Journal of Obesity

SN - 2090-0708

M1 - 610908

ER -